through "big data" composed of the above-mentioned omics on blood, cerebrospinal fluid, and brain samples from autopsy materials. Luckily, development of large-scale omic platforms (6) and progress in various neuroimaging modalities (5) together with advances in bioinformatics and computational programming have already started to generate "big data" information from AD patients and age-matched healthy cohorts. The accompanying review article by H. Zetterberg (7), which is the first in a Themed set of Reviews on "Omic and Systems Biology Approaches in Neurodegenerative Diseases," succinctly reviews the advances made in the field. The omic studies advance our knowledge of AD at multiple levels. These data help identify biomarkers that help in better disease diagnosis and help predict disease progression. More importantly, the omic data also help in understanding the potential pathogenic mechanisms and therefore yield new and efficacious therapies.
While these investigations at the systems levels utilizing human samples will certainly advance our understanding of the disease and bring us closer to an effective treatment of AD, many challenges still remain. Perhaps the most formidable challenge lies in elucidating the biological meaning of various omic data. By its very nature, the omic data tend to be heterogeneous and show wide variability. Thus, many assumptions are made by statisticians to make the underlying biological trends visible. However, such assumptions can also lead to false biological interpretation. Therefore, going forward, researchers who are comfortable with both biology and statistics will be required to identify and extract the correct biological meaning from the omic data. This will also require new statistical tools to analyze the data and identify the correct underlying biological information. However, ability to think in a nonlinear manner while analyzing the omic data for biological relevance will be important since simultaneous interactions between scores of proteins, lipids, and metabolites will rarely result in a simple deterministic outcome. Such fresh thinking will be the most crucial factor as new biological insights are applied to conceptualize AD disease mechanisms. Perhaps, lack of intellectual boldness and limited thinking may also have contributed to a string of failed clinical trials. Fig. 1 . A schematic view of how brain aging regulates the nonlinear interactions between various brain cell populations and pathogenic forms of tau and amyloid-␤ proteins affecting synaptic activity and neurocognitive functions. Healthy brain aging preserves these physiological interactions and maintains normal cognition. However, these interactions become dysfunctional as a result of unhealthy brain aging, which impairs synaptic activity and neurocognitive function and ultimately leads to AD.
